Overview

The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome

Positive Acute Lymphoblastic Leukemia (Ph+ B-ALL). We're looking at two groups of adults:

one group had an Allogeneic Stem Cell Transplant (alloHCT) cohort A, and the other group had chimeric antigen receptor T cell (CAR T) therapy, cohort B. We also want to figure out what the best dose of asciminib is to use moving forward in future studies.

Eligibility

Inclusion Criteria:

• Age ≥18 years
• Diagnosis of Ph+ B-ALL with detectable Philadelphia chromosome abnormalities
• Morphologic remission (\<5% marrow blasts)
• ECOG performance status 0-2
• Adequate organ function

Exclusion Criteria:

• Active relapsed disease (\>5% blasts)
• Grade II-IV acute GVHD requiring systemic steroids
• Significant organ dysfunction or uncontrolled infection
• Pregnancy or breastfeeding
• Prior investigational CAR T product